Rocket Pharmaceuticals Stock Surges with EU Approval for Gene Therapy Review
Tuesday, 2 April 2024, 10:55
Rocket Pharma Stock Surges with EU Approval
Rocket Pharmaceuticals (RCKT) experiences a surge in stock value following the acceptance of its marketing application by the European Medicines Agency for gene therapy RP-L102 targeting Fanconi anemia.
Advancement in Gene Therapy Research
This indicates a positive market response to the advancement in gene therapy research and Rocket Pharma's potential in addressing genetic disorders.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.